Introduction
Soft tissue sarcomas (STS) are a rare group of cancers compromising ~ 1% of all malignancies. There has been a slight increase in incidence, and half of STS patients are over the age of 65 years. 1 The pathogenesis of most STS remains unknown. Genetic, environmental and immunological factors have been identified as risk factors. It is likely that the cause of STS is multifactorial.
STS may arise in any part of the body, predominantly in the extremities (45%; lower limb 29%, upper limb 16%), trunk (25%), head and neck (13%), and retroperitoneum (8%) [1] . The tumors are graded according to the French grading system, distinguishing low-,
intermediate-and high-grade STS, and staged according to the American Joint Committee on
Cancer staging system. More practical for daily clinical practice is to distinguish between low-and high-grade, and between tumor sizes <5, 5-10 and >10 cm, as suggested by Brennan. 3 Insight into the disease and progress achieved with surgical technical skills and combined modality approach in these tumors have reduced the local failure rate and improved limb salvage figures. One-third to half of patients diagnosed with STS will die of their disease because of either metastatic disease or currently infrequently diagnosed locally recurrent disease. 4 The high-risk patient with extremity STS for distant metastasis and local recurrence is the patient with a large (T2), high-grade, deep lesion. The role of primary surgery as primary treatment and intervention in multidisciplinary sarcoma treatment is reviewed.
Landmarks in surgical treatment
In the past century, STS were simply resected, with local failure rates of 60% to 80%. There was a major movement in the late 1940's and early 1950's towards more radical surgical procedures, such as amputation or radical local resection, as first-line treatment. A sharp increase in local control was encountered. Up to the end of the 1970's, half of all limb sarcomas were treated by amputation. Although the local failure rate achieved with this surgical approach was only 10% to 15%, a large proportion of patients (30% to 40%) continued to die of metastatic disease. Surgical resection of metastatic disease, by example isolated lung metastases, improved the disease-free and overall survival of patients. 9 The most recent breakthrough in sarcoma treatment was the introduction of the drug targeting therapy with imatinib in the treatment of disseminated gastrointestinal stromal tumors. 10 The role of (interval) surgery within drug targeting therapy is currently being explored.
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Surgical approach
The surgical approach in STS is determined by several factors: tumor location, size of tumor, depth of invasion (superficial or deep), involvement of nearby structures, and possibility of primary wound closure and/or plastic surgery reconstruction. Beside these factors, patient performance and stage of disease are additional important factors in the surgical decision process. Although a large proportion of patients receive combined modality treatment, patients with localized disease can be treated with surgery alone. However, precise clinical pathological criteria for selecting patients for unimodality therapy are currently lacking.
Chapter 3 34
Operative procedures in sarcoma surgery have been described excellently by Malawer and Sugarbaker.
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Biopsy
What kind of biopsy is appropriate in the diagnostic process and treatment of a patient with a soft tissue mass? After taking medical history and performing physical examination, the tumor is first locally staged with MRI or CT scan before any biopsy. 5 Positron emission tomography might allow differentiation between a benign and malignant tumor. 13 Based on the results of the imaging techniques, whether the appropriate biopsy technique is incisional, excisional, core-needle biopsy (CNB) or fine needle aspiration (FNA) is discussed.
The diagnostic accuracy of a CNB in referral centers is equivalent to incisional biopsies, although it may be difficult to differentiate a low-grade malignancy from a benign tumor mass. 14 In the event that a diagnosis is not clarified by CNB, additional CNB samples can be FNA and CNB are useful in the diagnostic process of a local recurrence or metastatic disease.
Careful attention should be paid to the biopsy site and the prevention of ecchymosis, e.g.
tumor cell contamination. An inappropriately planned or poorly performed biopsy might seriously compromise subsequent surgical resection and even necessitate amputation.
Therefore, core-needle and open biopsies should be carefully planned, and performed at the sarcoma center where the definitive surgery is to be undertaken. Surgical biopsy tracks are excised routinely with the tumor specimen at the time of the definitive resection of the tumor.
Whoops approach
Sarcomas are still diagnosed after an unplanned excision, the so-called 'whoops approach'.
The pathology report will describe an R1 (microscopically involved margin) or R2
(macroscopically involved margin) resection requiring further therapy. If further surgery may render a patient disease-free (R0 resection) or an R2 might become an R1 resection, reresection is essential. If this aggressive surgical policy is applied, these patients are not apparently at risk for a worse outcome as compared with patients primarily referred to a multidisciplinary sarcoma unit. 15 The study from the Memorial Sloan-Kettering Cancer Center (MSKCC) even suggests that patients undergoing two operations (excision followed by second re-excision) have improved survival compared with patients treated with a single definitive operation.
Local resection
In the late 1970s, compartment excision was advocated, while today the consensus is that in sarcoma surgery, a wide local resection, R0 resection with a 2 cm margin, is an adequate resection. In the majority of sarcoma resections, a 2 cm margin is impossible to achieve due to anatomical structures, and an R1 resection is the best achievable resection margin. R2
resections should be avoided. Adjuvant radiation after R1 resection improves the local control rate (see also radiotherapy and chemotherapy below). Positive microscopic resection margins significantly decrease the local recurrence-free survival rate and independently predict distant recurrence-free survival and disease-specific survival rates in STS treatment. 16 If local resection of a sarcoma of the limb is impossible, amputation or disarticulation of the involved limb should be performed to render the patient disease-free. Sometimes extensive ablative surgical resections are required.
Surgical treatment of retroperitoneal STS is a challenge for the surgical oncologist, although the majority of these tumors are unresectable. Only radical tumor resection, often with resection of nearby organs, can render a patient disease-free. 17 The surgical margins are always minimal and the local failure rate is high, especially in high-grade tumors. 18 Palliative surgical procedures may be performed to address symptoms (intestinal obstruction, bleeding).
Chemotherapy is ineffective, post-operative radiotherapy may cause radiation enteritis and preoperative radiotherapy is hardly used. Drug targeting therapy with imatinib changed the prognosis of GIST.
Ablative surgical procedures
Forequarter amputation
Sarcomas of the shoulder girdle are frequently large and deepseated at initial presentation, and difficult to manage. For a small group of patients, a forequarter (interscapulothoracic) amputation is the only treatment option, and in a few cases a Tikhoff-Lindberg procedure, which allows for preservation of the limb, is feasible. On the other hand, for some patients an extensive resection with a part of the thoracic wall is necessary to achieve free surgical margins. Interthoracoscapular amputation is one of the most major ablative surgical procedures, which can be performed with curative or palliative intent, with minimal treatment-related morbidity. The prognosis does not differ from STS in general. 19, 20 Chapter 3
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Hindquarter amputation
The majority of STS of the upper thigh and buttock can potentially be treated with local excision, preserving the limb. For a few sarcomas of the lower limb or buttock region, a curative or palliative hindquarter amputation is unavoidable. The prognosis of these sarcomas after curative surgical treatment is not different from sarcomas in general. Wound healing disturbances are a major problem in the treatment of sarcomas in this anatomical region. 21 
Buttockectomy
Locally advanced soft tissue tumors of the buttock region represent a group of tumors with specific difficulties common to pelvic tumors, often large and deeply attached at initial presentation, and in the past treated with a hemipelvectomy. The majority of patients might now be treated with a complete en bloc resection of the gluteus muscles. 22 This procedure can be converted into an anterior hemipelvectomy if the tumor penetrates the deep margin of the muscle or infiltrates the bone. Involvement of the sciatic nerve is currently not longer an indication for a hemipelvectomy, since resection of the sciatic nerve is well tolerated, requiring only a brace. 23 
Hind foot amputation
Less than 10% of lower extremity sarcomas arise in the foot. In this location, limb-saving surgery is seldom possible and below-knee amputation is indicated. For selected tumors located at the forefoot, different hindfoot amputations are available, being excellent alternatives to a below-knee amputation.
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Interval surgery
Interval surgery is defined as a surgical procedure followed by induction treatment with chemotherapy and/or radiation for a solid tumor followed by surgery. The goal of the combined treatment strategy in STS is to improve the limb salvage rate, local tumor control and/or survival. Interval surgery is applied in the treatment of bone sarcomas, extra-osseous Ewing's sarcoma, primitive neuroectodermal tumor and rhabdomyosarcoma. There is a limited experience with interval surgery for STS with isolated limb perfusion, neo-adjuvant chemotherapy, intra-arterial chemotherapy and preoperative irradiation.
Isolated limb perfusion
In the first trial of ILP for STS, Krementz 24a showed an early response rate of 83% after melphalan; however, complete regression of the tumors was rarely seen. The results achieved with ILP were not better than for surgery and adjuvant radiation therapy. 25 Other perfusion agents were investigated. Doxorubicin and cisplatin were also ineffective, while doxorubicin combined with melphalan was too toxic. [26] [27] [28] The resurrection of interest in the ILP technique came with the introduction of tumor necrosis factor (TNF)-α and melphalan into the perfusion of primarily unresectable STS of the limb [8] . After a so-called TNF perfusion, a remarkable shrinkage of the tumor was encountered within 6-12 weeks, and unresectable sarcomas became resectable.
A large European study proved the ILP concept in the limbsalvage procedures for unresectable STS with TNF-α and melphalan. The objective response rate was 76%. A limb salvage rate of 71% was achieved, with minimal treatment-related morbidity. 8 An independent review committee considered that 80% of all enrolled patients in this study met the criteria for irresectability. 29 Further analysis showed that ILP patients survived as long as matched controlled conventionally treated patients. 29 Since the resection margins in these tumors are minimal and viable tumor cells are often encountered at the periphery of the tumor, radiation is indicated to ensure local tumor control. Adjuvant radiation is well tolerated after ILP and extensive surgical resection. 30 TNF perfusion has now been used for over a decade, and in surviving patients the long-term treatment-related morbidity necessitating amputation is low. 31 The outcome of the ILP procedure in 'elderly' sarcoma patients is in general not different from in 'younger' sarcoma patients. 32 Perfusions in elderly limb sarcoma patients, on the other hand, sometimes cannot be performed due to atherosclerotic changes in the main arteries and/or severe comorbidity.
Why do all perfused sarcomas not respond to a TNF-α ILP? Multidrug resistance (MDR) is a major issue in chemotherapy treatment. Two groups investigated the expression of MDR in patients undergoing TNF perfusion treatment and showed that temperature and drugs were unable to induce MDR-positive sarcomas. 33, 34 This is an important finding, since systemic doxorubicin-based polychemotherapy is currently being investigated in STS patients after 
Neo-adjuvant chemotherapy
The idea behind neo-adjuvant chemotherapy for locally advanced STS is: (i) tumor cytoreduction to render local surgery less extensive; (ii) early treatment of occult metastatic disease; and (iii) in vivo evaluation of the tumor's chemosensitivity. The EORTC performed a randomized phase II trial with doxorubicin 50 mg/m 2 and ifosfamide 5 g/m 2 versus local therapy alone. Owing to slow accrual, the trial was not extended to a phase III trial. There was no difference in the 5-year survival rate: 64% in the no-chemotherapy arm versus 65% for the control arm, and no conclusions could be drawn from the trial. 35 The trial showed no increase in surgical morbidity or improved local control. Based on the meta-analysis study, as well as recent data from Italy, there is still interest in the use of preoperative chemotherapy in the treatment of locally advanced STS. 36, 37 The question is whether surgeons and their patients are willing to participate in such a trial.
Drug targeting therapy
Complete surgical resection is the most important prognostic factor for patients with GIST.
Local recurrences and metastatic disease are frequently encountered after surgery for GIST.
Recently, a breakthrough in the treatment of disseminated GIST was observed with the introduction of imatinib. The preliminary results are impressive. The role of surgery is currently unknown for patients treated for metastatic GIST, as well as for patients who are unresectable and receive induction imatinib therapy. It is clear that in the near future, the role of surgery in locally advanced and metastatic GIST, as well as the role of imatinib, will be defined.
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Intra-arterial chemotherapy
The idea behind the intra-arterial chemotherapy was the 'first pass through effect' of the cytostatic agent. In the late 1970's, Eilber et al. 38 developed, for locally advanced limb sarcoma, a 3-day regimen of continuously intra-arterial doxorubicin with preoperative highdose fractionation radiation schedules of different dose levels. The initial results in the early 1980's were so promising that the treatment was adopted by the Groningen University
Hospital. The treatment was indeed effective, but the treatment-related morbidity was too high. Severe long-term treatment-related morbidity was encountered; 60% of the survivors developed serious functional problems varying from fibrosis to pathological stress fractures and invalidating neuropathy. 39 Since 1975, 753 patients have been treated at the University of Soft tissue sarcoma: role of surgery
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California at Los Angeles for a primary or recurrent sarcoma of the limb; 498 patients received neo-adjuvant therapy with intra-arterial doxorubicin and different radiation dose schedules. The study showed only a benefit of neo-adjuvant treatment in patients with recurrent sarcomas. Three-quarters of all recurrences were diagnosed within 36 months. When a local recurrence occurred, an amputation was unavoidable in 38% of cases. 38 Intra-arterial chemotherapy has no advantage over systemic drug delivery, and doxorubicin acts in this treatment mainly as a radiation sensitizer.
Preoperative radiation therapy
External beam radiotherapy delivered either pre-or postoperatively is highly effective in preventing local recurrences in patients who have a high risk for local failure, without any significant change in overall survival. 40 Adjuvant radiation is mostly used after marginal Cancer Center suggested that local control might be improved for patients with measurable disease treated with preoperative radiation. 41 A randomized trial of pre-versus post-operative radiotherapy in STS of the limb showed that preoperative radiotherapy was associated with a significant increase in wound healing complications, and did not warrant the further use of preoperative radiation in STS. 42 In contrast, preoperative radiotherapy is well accepted in the treatment of retroperitoneal sarcoma, to improve the local control rate while reducing the radiation induced morbidity, and sophisticated treatment schedules in which preoperative radiotherapy is combined with doxorubicin and intraoperative radiotherapy are promising for the surgical oncologist and radiation oncologist. 43 To further optimize the effectiveness of radiation treatment in locally advanced sarcoma, molecular target agents are currently being developed for cytoprotective or cytotoxic pathways, and clinical trials are already under way.
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Surgery for recurrent disease
Local recurrence
The most significant independent factor for recurrence is surgical margin, followed by deep tumor location and tumor grade. 16 Local control after inadequate resection or recurrent sarcoma is equal to that of primary sarcomas, if negative margins can be obtained by surgery.
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Metastasectomy
Approximately 30% to 40% of patients with high-grade sarcomas develop hematogenous metastases, predominantly to the lungs. Less than 3% of STS patients develop lymphogenic metastases. Patients with clear cell sarcoma, embryonal rhandomyosarcoma, epitheloid sarcoma and angiosarcoma are especially at risk, and the incidence in these tumors might be as high as 20%. 1 Although the lungs might be the primary site for distant failures in threequarters of patients, other sites of metastasis include the skin and soft tissues of the head and neck, trunk, and extremities. The median survival after the diagnosis of metastatic disease from primary extremity sarcoma is ~ 1 year, with no difference between pulmonary and nonpulmonary metastases. 45 Pulmonary metastases from STS are in general diagnosed with conventional X-rays and further staged with CT. If resection of all metastatic disease seems possible, a unilateral, bilateral or median sternotomy is advised. Approximately 60% to 80% of these patients might be rendered disease-free after surgical resection of the lung metastases, with a 5-year survival ranging from 20% to 40%. Long-term survival is possible in selected patients, but is exceedingly rare [46] . The EORTC experience showed a 3-year survival rate of 54% among patients undergoing complete resection of metastatic disease confined to the lungs, comparable to the MSKCC experience, with a 3-year actuarial survival of 46%. 47 Despite successful metastasectomies, a large proportion of patients will recur in one or both lungs. A second or even a third thoracotomy might be considered to render the patients disease-free. 48 Lymphogenic metastases are treated with a radical lymphadenectomy with a 5-year survival rate of >30%. Soft tissue masses are generally easy to resect, and resection might improve local control and quality of life. The only curative treatment option for metastatic disease is surgery, which can be performed with minimal treatment-related morbidity and mortality.
Surgery for complications
The risk for complications is related to the extent of surgery, the overall and local condition of The management of late (wound) complications requires much surgical expertise, and adequate treatment is seldom possible.
Plastic surgery reconstruction
The tactical and technical surgical parameters in sarcoma surgery are well defined in order to diminish the complication rates during tumor biopsy and definite resection. Reconstructive plastic surgery procedures by tissue transfer and microvascular surgical techniques play a key role in coverage of major defects and prevention of wound healing problems, and should be used more liberally; prevention is better than cure. 
Conclusions
